Singapore, July 6 -- Ascletis Pharma has submitted two Investigational New Drug applications to the U.S. FDA for obesity treatment candidates ASC36 and ASC36_35 FDC.

ASC36 is a next-generation peptide amylin receptor agonist being developed as a once-monthly to once-quarterly subcutaneous injection. ASC36_35 FDC is a once-monthly fixed-dose co-formulation combining ASC36 with ASC35, a peptide GLP-1R/GIPR agonist.

The filings are relevant because obesity drug development is moving rapidly beyond first-generation incretin-based therapies. While GLP-1 and GLP-1/GIP therapies have reshaped the market, there is growing interest in longer-acting and multi-mechanism approaches that may improve efficacy, dosing convenience and long-term adheren...